Collaboration with aTyr Pharma Announces Research
to Identify 10 New Therapeutic Targets
Dualsystems Biotech is very excited to start a 3 year non-exclusive collaboration with aTyr Pharma to identify 10 novel therapeutic drug targets.
With our LRC-TriCEPS platform we can identify targets on living cells and have identified in the past many novel interactions.
Contact me here if you would like to learn more about our LRC-TriCEPS platform and how it can support your drug discovery research
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research collaboration with Dualsystems Biotech AG, a company specializing in custom proteomics, aimed at accelerating drug discovery and generating new therapeutics based on aTyr’s extensive intellectual property (IP) portfolio. Under the collaboration, which is exclusive with respect to tRNA related molecules, Dualsystems will utilize their proprietary receptor screening technology and research expertise to attempt to identify and validate 10 new target receptors for tRNA synthetases by 2025.
“We are delighted to build upon the impactful discovery work that we have accomplished with Dualsystems thus far,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We were impressed with the work that this highly specialized company conducted to identify fibroblast growth factor receptor 4 (FGFR4) as the target receptor for a fragment of alanyl-tRNA synthetase (AARS), and we are eager for them to showcase their cutting-edge technology further by applying it to additional tRNA synthetases from our IP. We look forward to discoveries from this collaboration as a way to potentially accelerate drug discovery efforts and identify new drugs from our platform.”
Read more in the PDF